A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0)

Trial Profile

A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms POST
  • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to completed, according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2012 Trial design reported at ASCO 2012.
    • 05 Jun 2012 Planned number of patients changed from 166 to 290. According to an abstract reported at ASCO 2012, 67 of 290 patients have been treated, with accrual continuing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top